| Filed On | Filing |
|---|---|
| 09 Nov 2026 | SCHEDULE 13G |
| 09 Nov 2026 | SCHEDULE 13D/A |
| 29 Oct 2026 | 10-Q |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif. – October 29, 2026 - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, cli... |
| 11 Sep 2026 |
8-K: Other Events
Today, Exelixis, Inc. (Exelixis) announced that on September 10, 2026, the U.S. Food and Drug Administration (FDA) notified Exelixis that it had extended the review period for Exelixis’ new drug application (NDA) for zanzalintinib, in co... |
| 31 Aug 2026 |
8-K: Other Events
On August 31, 2026, Exelixis, inc. (Exelixis) announced that the U.S. Court of Appeals for the Federal Circuit (Court of Appeals) issued a decision in Exelixis, Inc. v. MSN Laboratories Private Limited et al., Appeal No. 25-1236, affirmi... |
| 14 Aug 2026 | SCHEDULE 13D/A |
| 12 Aug 2026 |
Form 4: Beckerle Mary C, Director
Sold 9,812 shares ($527K) |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 10 Aug 2026 | 144 |
| 05 Aug 2026 | S-8 |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif. – August 5, 2026 - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clin... |
| 03 Jun 2026 |
Form 4: Wyszomierski Jack L, Director
Sold 3,925 shares ($198K) |
| 03 Jun 2026 |
Form 4: Eckhardt Sue Gail, Director
Sold 9,812 shares ($492K) |
| 01 Jun 2026 | 144 |
| 01 Jun 2026 | 144 |
| 29 May 2026 |
Form 4: Papadopoulos Stelios, Director
Received 8,367 shares as a grant or award |
| 29 May 2026 |
Form 4: Heyman Tomas J., Director
Received 8,367 shares as a grant or award |
| 29 May 2026 |
Form 4: Eckhardt Sue Gail, Director
Received 8,367 shares as a grant or award |
Loading...